Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A, Reck M, IMpower150 Study Group.

Open source

DOI: 10.1056/nejmoa1716948
Published: 2018-06-04
Container: N Engl J Med
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1056/nejmoa1716948,
  title = {Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.},
  author = {Socinski MA and  Jotte RM and  Cappuzzo F and  Orlandi F and  Stroyakovskiy D and  Nogami N and  Rodríguez-Abreu D and  Moro-Sibilot D and  Thomas CA and  Barlesi F and  Finley G and  Kelsch C and  Lee A and  Coleman S and  Deng Y and  Shen Y and  Kowanetz M and  Lopez-Chavez A and  Sandler A and  Reck M and  IMpower150 Study Group.},
  year = {2018},
  journal = {N Engl J Med},
  doi = {10.1056/nejmoa1716948},
  url = {https://doi.org/10.1056/nejmoa1716948}
}

RIS

TY  - JOUR
TI  - Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
AU  - Socinski MA
AU  -  Jotte RM
AU  -  Cappuzzo F
AU  -  Orlandi F
AU  -  Stroyakovskiy D
AU  -  Nogami N
AU  -  Rodríguez-Abreu D
AU  -  Moro-Sibilot D
AU  -  Thomas CA
AU  -  Barlesi F
AU  -  Finley G
AU  -  Kelsch C
AU  -  Lee A
AU  -  Coleman S
AU  -  Deng Y
AU  -  Shen Y
AU  -  Kowanetz M
AU  -  Lopez-Chavez A
AU  -  Sandler A
AU  -  Reck M
AU  -  IMpower150 Study Group.
PY  - 2018
JO  - N Engl J Med
DO  - 10.1056/nejmoa1716948
UR  - https://doi.org/10.1056/nejmoa1716948
ER  -

APA

MA, S., RM, J., F, C., F, O., D, S., N, N., D, R., D, M., CA, T., F, B., G, F., C, K., A, L., S, C., Y, D., Y, S., M, K., A, L., A, S., M, R., & Group., I. S. (2018). Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.. N Engl J Med. https://doi.org/10.1056/nejmoa1716948

Source records

europe-pmc · retrieved 2026-09-26T10:30:40.073Z